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Abstract
Purpose Monoclonal antibodies (mAb) are an important
and growing class of cancer therapeutics, but pharmacoki-
netic analyses have in many cases been constrained by the
lack of standard and robust pharmacologic assays. The goal
of this project was to develop a general method for the
production of immunoassays that can measure the levels of
therapeutic monoclonal antibodies in biologic samples at
relevant concentrations.
Methods Alemtuzumab and rituximab are monoclonal
approved for the treatment of B-cell malignancies and were
used as a model system. Phage-displayed peptide libraries
were screened for peptide sequences recognized by
alemtuzumab (anti-CD52) or rituximab (anti-CD20). Syn-
thetic biotinylated peptides were used in enzyme-linked
immunosorbent assays (ELISA). Peptides directly synthe-
sized on polymer resin beads were used in an immunoXuo-
rescent-based assay.
Results Peptide mimetope sequences were recovered for
both mAb and conWrmed by competitive staining and
kinetic measurements. A peptide-based ELISA method was
developed for each. The assay for rituximab had a limit of
detection of 4 g/ml, and the assay for alemtuzumab had a
limit of detection of 1 g/ml. Antibody-speciWc staining of
peptide conjugated beads could be seen in a dose-depen-
dent manner.
Conclusion Phage-displayed peptide libraries can be a
source of highly speciWc mimetopes for therapeutic mAb.
The biotinylated forms of those peptides are compatible
with conventional ELISA methods with sensitivities com-
parable to other assay methods and suYcient for pharmaco-
logical studies of those mAb given at high dose. The
process outlined here can be applied to any mAb to enable
improved pharmacokinetic analysis during the develop-
ment and clinical use of this class of therapies.
Keywords Immunoassay · Monoclonal antibody · 
Peptide · ELISA · Phage display
Introduction
Monoclonal antibodies are used in the treatment of many
cancers and proliferative diseases [1]. Dynamic monitoring
of monoclonal antibody therapy has the potential to person-
alize these treatments for the beneWt of patients and to
lower costs. There are currently eleven approved monoclo-
nal antibody therapies for cancer with an almost equal num-
ber approved for other conditions, most notably
autoimmunity and transplant rejection. Several hundreds
are in development. The pharmacology of mAb presents a
particular challenge during clinical development, because
they often have very mild acute toxicities at high doses.
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Traditional paradigms of dose escalation until a maximally
tolerated dose is found may not be optimal. As a result, the
development of dosing schedules is somewhat arbitrary and
can be inXuenced by the high cost of mAb therapies.
Several approaches have been used to study the phar-
macokinetics of these treatments. The target molecule can
be produced in a recombinant system for sandwich ELISA
[24]. However, it may not always be possible to generate
the recognized portion of the target molecule, and it is
expensive and cumbersome to generate large amounts of
recombinant protein. Peptides designed from the target
antigen sequence have been tried in lieu of recombinant
antigens, with limited success [4]. An alternate approach is
to express the target molecule on a cell line by transfec-
tion, using Xow cytometry to assess the binding of the
desired mAb [22]. This method has been used for ale-
mtuzumab (anti-CD52) but is diYcult to develop, requires
skilled personnel to execute, and has limited sensitivity
[8]. Finally, ELISA have been developed that used anti-
bodies speciWc for the therapeutic mAb [19]. The antibod-
ies used for this purpose are either anti-idiotypic [13] or
speciWc for residual non-human sequences of the therapeu-
tic mAb, as was the case with alemtuzumab [10]. How-
ever, each of these approaches is technically demanding
and has limited sensitivity when used in biologic samples
because of the background from the high levels of endoge-
nous antibody. The latter approach will not work with
fully humanized mAb.
Peptide libraries displayed on bacteriophage are rou-
tinely used to identify peptide epitopes, or mimetopes, rec-
ognized by antibodies. When short peptides, 7–12 amino
acids are screened, the selected peptides almost invariably
bind to the antigen-binding site of the antibody and are
competed by the natural ligand [17]. This property makes
such libraries ideal for the selection of epitope targets that
can be used in ELISA or other immunoassays.
Bead-based immunoassays are an alternative to plate-
based ELISA and have the several advantages. They can be
multiplexed with beads that are distinguishable by Xuores-
cence, size, or other physical parameters [23]. Beads can
mix with large volumes of sample and have improved anti-
gen-capture eYciencies compared to the surface of a well.
Beads can be made from a variety of materials that can be
optimized for the speciWc application. Automated solid
phase peptide synthesis is commonly performed on resin
beads [16]. One such resin is TentaGel, a graft copolymer
of a crosslinked polystyrene matrix and polyethylene glycol
[21]. TentaGel beads have been used extensively in biolog-
ical assays with combinatorial peptide libraries and show
very low non-speciWc protein adsorption [9,  11]. In this
study, we demonstrate a process that combines phage dis-
play discovery of mimetope peptides with solid phase
immunoassay methods for the quantiWcation of mAb levels
in biologic samples. The process used is general and should
be applicable to any mAb or other recombinant protein bio-
logic therapy.
Materials and methods
Antibodies
Alemtuzumab (Genzyme, Cambridge, MA) and rituximab
(Genentech, San Francisco, CA) were obtained from the
UCSD Cancer Center pharmacy. The antibodies were Xuo-
rescently labeled using the Zenon R-phycoerythrin human
IgG labeling kit, Zenon Alexa Xuor 488 human IgG label-
ing and Alexa Xuor 488 protein labeling kits (Invitrogen,
Carlsbad, CA). For kinetic studies, Fab fragments of each
mAb were prepared by papain digestion using a Fab prepa-
ration kit (Thermo Fisher ScientiWc, Rockford, IL) as per
manufacturer’s instructions.
Plasma samples
Blood was collected from consenting patients who satisWed
diagnostic and immunophenotypic criteria for B-cell
chronic lymphocytic leukemia (CLL) and who presented
for evaluation at the referral centers of the CLL research
consortium (CRC). Plasma was obtained by standard
methods.
Peptide library screening
Three phage-displayed peptide libraries (Ph.D 7, Ph.D. 12,
and Ph.D. C7C, New England Biolabs, Ipswich, MA) were
combined and screened against the mAbs as previously
described [17]. BrieXy, the mAb were coated onto ELISA
plates at a concentration of 1 g/ml and incubated at 4°C
overnight. The coating solution was removed, and the wells
blocked with 2.5% bovine serum albumin (BSA) in tris
buVered saline (TBS). After 1 h at 4°C, the blocking solu-
tion was removed, the wells washed three times, and the
phage libraries added in a Wnal volume of 100 l in TBS.
After 1-h incubation at room temperature, the wells were
washed with TBS ten times, and the bound phage eluted for
10 min with 0.2 M Glycine–HCl (pH 2.2). The eluted
phage was neutralized with Tris–HCl (pH 9.1) and grown
on K91 bacteria overnight. The bacteria were pelleted, the
culture supernatant passed through a 0.2-m syringe tip
Wlter, and the phage precipitated with 2.5 M NaCl–20%
polyethylene glycol (PEG). The phage pellet was resus-
pended in TBS, and the next round of selection done as
above. After the Wnal round of selection, individual phage
clones were picked and sequenced using the -96gpIII
primer provided with the library kits.Cancer Chemother Pharmacol (2010) 66:919–925 921
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Peptides
Peptides were ordered from Sigma-Genosys (St. Louis,
MO). The alemtuzumab-binding peptide, pCp-1, had
sequence ACGSLSPSSCGGGS. Biotinylated peptides,
pCp-1B, had sequence ACGSLSPSSCGGK, and ritux-
imab-binding peptide, pRTX-10B, had sequence ACPYSN
PSLCGGK. Both peptides were biotinylated via the C-ter-
minal lysine to maintain the same anchoring orientation
as was the case when the peptide was displayed on the
phage protein. The peptides were puriWed to 95 and 82%,
respectively, by the manufacturer. Peptide–bead conjugates
were obtained from Peptides International (Louisville,
KY). The alemtuzumab-binding peptide beads, pCp-1T,
had sequence ACGSLSPSSCGGGS, and the rituximab-
binding peptide beads, pRTX-10T, had sequence
ACPTSNPSLCGGGS. Both were acetylated at the N terminus
and coupled to 10 m TentaGel beads at the C-terminus.
Binding kinetics
Kinetics of antibody–peptide binding was studied using
SkiProTM biomolecular interaction technology 1 on a Ski-
Pro interferometer equipped with a 2-channel Xow cell and
an autosampler (Silicon Kinetics Inc., San Diego, CA). All
reagents were purchased from Sigma–Aldrich, St. Louis,
MO. All peptides were incubated with oxidizing agent
sodium tetrathionate at 10 mM in phosphate buVered saline
(PBS) for 1 h immediately before binding experiments.
Biotinylated peptides were diluted to 5 M in PBS/0.05%
BSA and immobilized on streptavidin-coated Ski Sen-
sorTM Biochips for 10 min at 4 l/min  Xow rate. That
resulted in optical path diVerence shift (OPD) of 5–6 nm.
Concentration series of antibodies and antibody Fab frag-
ments were prepared as twofold dilutions in PBS/0.05%
BSA. Binding was carried out for 10 min followed by 20-
min dissociation. For all sensorgrams, reference channel
data were subtracted from the sample channel. The resulting
multi-concentration series of binding curves were globally Wt
to a single binding site association/dissociation model.
CLL cell staining
After informed consent was obtained per the declaration of
Helsinki, blood samples were collected from patients at the
University of California, San Diego (UCSD) Medical Cen-
ter who satisWed diagnosis and immunophenotypic criteria
for common B-cell CLL.
CLL cells (105/per well) were seeded into 96-well plates
in 100 l of X-vivo medium (BioWhittaker, Walkersville,
MD) and incubated with Zenon labeled alemtuzumab or
rituximab (0.5 g/well) for 1 h on ice. After, cells were
washed two times with 100 l FACS-wash (PBS, 5% FCS
and 0.5% sodium azide) and Wxed with 100 l with 3.7%
formaldehyde in PBS.
ELISA
Each well in a 96-well NeutrAvidin coated plate (Pierce,
Rockford, IL) was coated with 100 l of a solution of bio-
tinylated peptide at 30 g/ml in ddH2O and incubated for
1 h at room temperature. A reference well was left
uncoated but Wlled with buVer. Wells were washed Wve
times with TBS/0.05% Tween-20 (TBST) using an auto-
mated plate washer (Columbus Pro, Tecan, Durham, NC).
Non-speciWc binding sites were blocked by incubation
with 300 l of 5% BSA/TBS for 2 h at room temperature.
Wells were washed Wve times with TBST wells and were
Wlled with 100 l of standard or sample. Plasma samples
were diluted in 2.5% BSA/TBST 1:500 for alemtuzumab
assays and 1:1000 for rituximab assays. All samples were
analyzed in triplicate on both peptide-coated and uncoated
wells. Standard curves were assayed in triplicate. Plates
were incubated for 1 h at room temperature and then
washed with TBST. Hundred microliters of goat anti-
human IgG POD antibody (Jackson Immunoresearch,
West Grove, PA) was added at dilution 1:5000 in TBST
for 30 min at room temperature. Wells were washed ten
times with TBST. Hundred microliters/well of turbo TMB
(Pierce) substrate was added and incubated for 15–
45 min. The reaction was stopped with 100 l of 1 M sul-
furic acid, and the absorbance was measured at 450 nm on
an InWnite M200 plate reader (Tecan). For peptide block-
ing experiments, the antibody was pre-incubated with
12.5 g/ml of the free peptide.
For all samples and standards, the absorbance reading of
each sample on an uncoated well was subtracted from the
sample assayed on a peptide-coated well. The diVerential
values for the standard curve were Wt with a one-site total
binding curve, and the sample values interpolated using
Graphpad Prism 5 software (Graphpad Software Inc., La
Jolla, CA).
Detection of alemtuzumab and rituximab on beads 
by Xow cytometry
Peptide beads, 6 £ 104 beads/sample, were mixed with
diVerent concentrations of the respective labeled antibody
for 16 h at 4°C in a rotator. The beads were washed twice
with PBS by centrifugation at 14,000 rpm for 2 min at
room temperature and were resuspended in 100 l of PBS.
Beads were analyzed on a BD FACSCalibur (Becton–Dick-
inson, Franklin Lakes, NJ), and the data analyzed on
FlowJo (Treestar, Ashland, OR) software.922 Cancer Chemother Pharmacol (2010) 66:919–925
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Results
A pool of three phage-displayed peptide libraries was
panned against rituximab and alemtuzumab. In each case,
signiWcant enrichment in the number of bound and recov-
ered phage was observed after three rounds. We selected
individual phage plaques from the Wnal enriched population
and determined the sequence of the displayed peptides
(Fig. 1). All of the peptides recovered were from the cys-
teine-containing library. The rituximab-binding peptide
sequences were identical to those identiWed in a previous
report [20]. The alemtuzumab-binding sequences shared a
motif and were similar in sequence to the extra-cellular
domain of CD52 [7]. Phage displaying either the rituximab-
or alemtuzumab-binding peptides was speciWc for the cog-
nate antibody and did not bind the other or normal human
IgG (data not shown).
Alemtuzumab-binding sequence, Cp-1, and rituximab-
binding sequence, RTX-10, were chosen for further analy-
sis. Biotinylated peptides were used for kinetic binding
measurements using nano-pore optical interferometry
(Fig. 1 in “Supplementary material”). The binding kinetic
parameters thus determined are given in Table 1. The Kd for
both peptide–mAb pairs was 100–200 nM when the intact
mAb molecules were used, but when Fab fragments were
used, the Kd was 2–4 M. This suggests that surface-immo-
bilized peptides are capable of bivalently interacting with
the two Fab regions of the intact molecule, producing a
greater binding avidity than the monovalent Fab–peptide
interaction.
To determine whether the peptides were binding to the
antigen-binding region of the mAbs, soluble synthetic pep-
tides were evaluated for their ability to inhibit the binding
of alemtuzumab and rituximab to the surface of primary
CLL cells (Fig. 2). CLL cells express high levels of CD52
and low levels of CD20. Each peptide inhibited the binding
of the respective mAb to the CLL cells. There was no eVect
on the binding activity of the other mAb (data not shown).
This result indicted that the peptides could be used for
detection of free, active mAb.
Neutravidin plates were coated with the biotinylated
peptides for an ELISA. Representative titration curves for
each mAb in saline buVer are shown in Fig. 3. The binding
of the mAb to the peptide coated plates could be completely
inhibited by an excess of soluble peptide (Fig. 2 in “Supple-
mentary material”). Multiple individual serum and plasma
samples were used to optimize the dilution factor (data not
shown), and it was determined that a sample dilution of
Fig. 1 Phage-displayed peptide sequences. Phage-displayed libraries
were panned against alemtuzumab (top) and rituximab (bottom) for
three rounds, after which individual phage clones were picked and
sequenced. The deduced sequences of the displayed peptides are
aligned, with amino acid identity boxed. The numbers in parenthesis
indicate the number of independent clones found to have that
sequence. The sequences of Cp-1 and RTX-10 were selected for
further analysis as synthetic peptides
Table 1 Binding kinetics
Whole molecule Fab
RTX-10 Cp-1 RTX-10 Cp-1
Kon, M¡1
£ s¡1
7.51E + 03 8.13E + 03 1.63E + 03 2.46E + 03
KoV, s¡1 9.84E ¡ 04 1.32E ¡ 03 6.51E ¡ 03 5.05E ¡ 03
Kd 131 nM 163 nM 3.99 M2 . 0 5 M
Fig. 2 Peptide inhibition of 
CLL cell staining. Fluorescently 
labeled alemtuzumab (a) or rit-
uximab (b) was incubated with 
primary CLL cells and evaluated 
by Xow cytometry (solid line). 
As expected, robust staining 
with alemtuzumab was seen, 
while the staining for CD20 with 
rituximab was weak. When pep-
tides pCp-1B or pRTX-10B 
were added at a 25,000 M excess 
(dashed lines), the cell labeling 
as largely abrogated. The shaded 
histogram represents CLL cells 
incubated with Xuorescently 
labeled normal human IgGCancer Chemother Pharmacol (2010) 66:919–925 923
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1:1000 for rituximab and 1:500 for alemtuzumab provided
the optimal balance between sensitivity and elimination of
matrix eVects. Furthermore, we found that variations in the
level of background signal between samples could be com-
pensated for by testing each sample against both peptide
coated and uncoated well and using the diVerence.
The limit of blank was determined by analyzing plasma
samples from patients with CLL who had not received
mAb therapy. Eighty-Wve samples from 60 diVerent indi-
viduals were analyzed using the rituximab peptide assay
and 48 unique samples using the alemtuzumab peptide
assay. The limit of blank (the 95th percentile of the nega-
tive samples) was 1.76 g/ml for the rituximab ELISA
and 0.53 g/ml for the alemtuzumab assay. The limit of
detection was determined by analyzing six diVerent
spiked samples on four diVerent days. The lowest concen-
tration at which the lower 95th percentile was above the
limit of blank was 4 g/ml for rituximab (lower 95th:
1.88 g/ml) and 1 g/ml for alemtuzumab (lower 95th:
0.83 g/ml). The limit of quantitation, deWned as the con-
centration at which the coeYcient of variation is <15%,
was 32 g/ml for rituximab and 8 g/ml for alemtuzumab.
The high degree of variation in the rituximab assays may
be due in part to varying levels of cell-free CD20 in the
plasma of the CLL patients used, a well-known phenome-
non [14].
An advantage to using peptides as the primary capture
agent in solid phase immunoassays is that they can be
directly synthesized on a variety of substrates. To demon-
strate this, the rituximab and alemtuzumab peptides were
synthesized on 10-m diameter TentaGel beads, hereafter
known as pCp-1T and pRTX-10T. TentaGel, a PEG poly-
styrene co-polymer, is a common solid phase synthesis sup-
port material, and commercially prepared peptides are
typically cleaved from the surface of such beads. SpeciWc
cognate antibody binding was conWrmed by Xow cytometry
and  Xuorescent microscopy (Fig. 3 in “Supplementary
material”). Alemtuzumab was titrated into normal human
serum and incubated with the pCp-1T beads. After washing
and addition of a Xuorescent secondary anti-human IgG
antibody, the Xuorescence on the beads was quantitated by
Xow cytometry. The Xuorescent signals correlated with the
alemtuzumab concentration, with very little background
from serum alone (Fig. 4).
Fig. 3 Standard curves of alemtuzumab and rituximab by peptide-
based ELISA. Biotinylayed peptides were bound onto neutravidin-
coated ELISA plates. Both alemtuzumab and rituximab antibodies
were diluted in TBST. Each value shows the mean (§SD) of tripli-
cates. The solid line indicates the mean of the buVer control, and the
dashed line represents the mean +10 times the SD of the buVer control
Fig. 4 Alemtuzumab bead-
based detection. DiVerent con-
centrations of labeled ale-
mtuzumab were analyzed by 
Xow cytometry using pC1-1T 
conjugated beads924 Cancer Chemother Pharmacol (2010) 66:919–925
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Discussion
The data described here demonstrate the general applicabil-
ity of peptide phage display to the development of mono-
clonal antibody-speciWc immunoassays. Phage-displayed
peptide libraries can be used to identify mimetope peptides
that bind to the antigen-binding site of antibodies in a spe-
ciWc and selective fashion. While it is theoretically possible
that peptides that bind to the constant region of the mono-
clonal antibody could be enriched, and would thus lack
speciWcity, this is not usually the case. The constant regions
of antibodies are generally refractory to short peptide
libraries, and even if they are selected, simple competitive
blocking schemes can be used [18]. Constant region bind-
ing peptides have been selected from longer libraries [5].
The peptides identiWed in this study were speciWc and com-
peted with the target cell surface antigen for mAb binding.
ELISA for serum or plasma antibody levels are typically
limited by the need to dilute the sample to lower the back-
ground due to non-speciWc binding of endogenous antibod-
ies that react with the secondary antibody. This was the
case for our peptide ELISA as well, though the limit of
detection achieved is comparable to or better than those
used for other therapeutic mAb [15]. In addition, we
observed patient-to-patient variation in the background that
could be accounted for by analyzing samples against both
peptide-coated and uncoated wells. The assays as described
here would be suYcient for analysis of mAb in patients
treated with high doses of Ab where the expected range of
interest is >4 g/ml. Since the primary goal of this study
was to develop the peptide ligands, the assays were not
completely optimized, and it is likely further reWnements to
the assay will lower the limit of detection and improve
reproducibility.
While the general pharmacokinetics of monoclonal anti-
bodies is well established, there can be large variation in
the achieved pharmacokinetics from one antibody or
patient to the next. Some of this variation may be related to
the treatment target as larger tumors can absorb more of the
mAb and result in lower serum levels. Population pharma-
cokinetic studies have shown that Wnal drug levels can vary
by as much as an order of magnitude among patients given
a standard body mass adjusted dose [6]. However, with the
exception of radiolabelled antibodies whose doses are per-
sonalized based on dosimetry and biodistribution, there is
no current practice to monitor mAb levels and tailor the
dose to the patient. Several studies with diVerent mAb have
suggested correlation between Wnal trough mAb levels and
therapeutic outcome [2, 12], indicating that real-time moni-
toring and patient-speciWc dosing may improve the success
rate achieved with these therapies.
Dosing schedules and routes of administration for mAb
are developed with many uncertainties and are often reWned
through pre-clinical and clinical studies where the need for
simple and reliable pharmacokinetic assays is acute. The
speciWc biology of a given mAb target can also lead to
additional complications from the conventional dose esca-
lation paradigm. For instance, there have been reports of
cell-free CD20 in the plasma of patients with CLL [14], and
other reports have suggested that CD20 may be “shaved”
from CLL cells consequent to rituximab treatment [25],
which may or may not aVect the detection of free rituximab
[3]. Since peptide mimetopes bind to the antigen-binding
site of the mAb and compete with the natural ligand, they
intrinsically measure only active mAb. The peptide-based
assays described here are ideal for the development of vali-
dated clinical assays, because they can be made cheaply at
high purity and can be synthesized directly on a variety of
substrates, such as the TentaGel beads shown here, that
may enable simple, automated point-of-care assay tools for
personalized therapy.
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